SYDNEY, Dec. 11, 2012 /CNW/ - http://www.sirtex.com informs doctors, patients and investors about the world's most widely
used and widely studied form of SIRT for all cancers in the liver
Sirtex today unveiled http://www.sirtex.com, a new, comprehensive and easy-to-use global website for doctors,
nurses, patients and investors interested in learning more about
SIR-Spheres microspheres, a form of radiotherapy targeting liver
tumours that is gaining increasingly wide acceptance worldwide.
"We faced some interesting challenges to make this website genuinely
helpful to the wide range of people who might visit it," said Gilman
Wong, Chief Executive Officer of Sirtex Medical Limited.
"For example, administering SIR-Spheres microspheres to patients
requires the skills of a team of doctors and nurses from medical
oncology, hepatology, gastroenterology, liver surgery, interventional
radiology, nuclear medicine and radiation oncology. Each discipline is
critical to meeting the needs of a patient with liver tumours, but all
have different perspectives and informational needs relative to
SIR-Spheres microspheres," he explained.
"The same holds true of patients. A patient with primary liver cancer,
or hepatocellular carcinoma (HCC), has a disease that is quite
different from a patient with metastatic colorectal cancer (mCRC), who
may have already undergone extensive surgical, radiation and
chemotherapy treatments before considering SIR-Spheres microspheres,"
Mr. Wong stated.
http://www.sirtex.com has specialised content for all these diverse audiences, as well as for
patient groups, through to those interested in investing in this
rapidly emerging technology. Content is also regionalised for Europe,
Asia-Pacific, Australia and the Americas.
"In addition to making our website useful to a cross-section of people
that is quite extensive for a therapy that is itself highly specific,
our other big challenge was to stay current with a rapidly growing
research data base, including a number of new studies that may lead to
the use of SIR-Spheres microspheres earlier and in a larger population
of patients with liver cancers," Mr. Wong added.
Visitors to http://www.sirtex.com may click through to independent sites about SIRFLOX (global) and
FOXFIRE (UK), two major studies of SIR-Spheres microspheres combined
with chemotherapy in mCRC patients who are at an early stage of
treatment, as well as SORAMIC (Europe), SIRveNIB (Asia-Pacific) and
SARAH (France), three large studies of SIR-Spheres microspheres alone
or in combination with sorafenib (Nexavar®) in patients with HCC.
About Selective Internal Radiation Therapy using SIR-Spheres
Selective Internal Radiation Therapy (SIRT), also known as
radioembolisation, is a novel treatment for inoperable liver cancer
that delivers high doses of radiation directly to the site of tumours.
In a minimally invasive treatment, millions of radioactive SIR-Spheres
microspheres are infused via a catheter into the liver where they
selectively target liver tumours with a dose of internal radiation up
to 40 times higher than conventional radiotherapy, while sparing
Clinical studies have confirmed that liver cancer patients treated with
SIR-Spheres microspheres have response rates higher than with other
forms of treatment, resulting in increased life expectancy, greater
periods without tumour activity, and improved quality of life. SIRT has
been found to shrink liver tumours more than chemotherapy alone.
Manufactured by Sirtex Medical Limited, SIR-Spheres microspheres are the
only FDA-PMA approved microsphere radiation therapy for the treatment
of liver metastases. Over 25,000 doses of SIR-Spheres microspheres
have been supplied worldwide.
SIR-Spheres microspheres are approved for use in Australia, the European
Union (CE Mark), New Zealand, Switzerland, Turkey and several other
countries including in Asia (e.g. India, Korean, Singapore and Hong
Kong) for the treatment of unresectable liver tumours. SIR-Spheres
microspheres are also indicated in the U.S. for the treatment of
non-resectable metastatic liver tumours from primary colorectal cancer
in combination with intra-hepatic artery chemotherapy using
SIR-Spheres® is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd
SOURCE: Sirtex Medical Limited
For further information:
Nathalie Amoury, Sirtex Medical: Email: firstname.lastname@example.org ; Andrea Moody, Fleishman Hillard, Raleigh NC, USA: Phone: +1-919-457-0744 , Email: email@example.com